These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
387 related articles for article (PubMed ID: 15546675)
1. Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose. Contrera JF; Matthews EJ; Kruhlak NL; Benz RD Regul Toxicol Pharmacol; 2004 Dec; 40(3):185-206. PubMed ID: 15546675 [TBL] [Abstract][Full Text] [Related]
2. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials. EFSA GMO Panel Working Group on Animal Feeding Trials Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408 [TBL] [Abstract][Full Text] [Related]
3. Prediction of rodent carcinogenic potential of naturally occurring chemicals in the human diet using high-throughput QSAR predictive modeling. Valerio LG; Arvidson KB; Chanderbhan RF; Contrera JF Toxicol Appl Pharmacol; 2007 Jul; 222(1):1-16. PubMed ID: 17482223 [TBL] [Abstract][Full Text] [Related]
4. Use of the dog as non-rodent test species in the safety testing schedule associated with the registration of crop and plant protection products (pesticides): present status. Box RJ; Spielmann H Arch Toxicol; 2005 Nov; 79(11):615-26. PubMed ID: 15940470 [TBL] [Abstract][Full Text] [Related]
5. Principles of risk assessment for determining the safety of chemicals: recent assessment of residual solvents in drugs and di(2-ethylhexyl) phthalate. Hasegawa R; Koizumi M; Hirose A Congenit Anom (Kyoto); 2004 Jun; 44(2):51-9. PubMed ID: 15198717 [TBL] [Abstract][Full Text] [Related]
6. Assessment of the health effects of chemicals in humans: I. QSAR estimation of the maximum recommended therapeutic dose (MRTD) and no effect level (NOEL) of organic chemicals based on clinical trial data. Matthews EJ; Kruhlak NL; Benz RD; Contrera JF Curr Drug Discov Technol; 2004 Jan; 1(1):61-76. PubMed ID: 16472220 [TBL] [Abstract][Full Text] [Related]
7. Precision of estimates of an ADI (or TDI or PTWI). Speijers GJ Regul Toxicol Pharmacol; 1999 Oct; 30(2 Pt 2):S87-93. PubMed ID: 10597619 [TBL] [Abstract][Full Text] [Related]
8. Ethyl methanesulfonate toxicity in Viracept--a comprehensive human risk assessment based on threshold data for genotoxicity. Müller L; Gocke E; Lavé T; Pfister T Toxicol Lett; 2009 Nov; 190(3):317-29. PubMed ID: 19443141 [TBL] [Abstract][Full Text] [Related]
9. Comparison of MC4PC and MDL-QSAR rodent carcinogenicity predictions and the enhancement of predictive performance by combining QSAR models. Contrera JF; Kruhlak NL; Matthews EJ; Benz RD Regul Toxicol Pharmacol; 2007 Dec; 49(3):172-82. PubMed ID: 17703860 [TBL] [Abstract][Full Text] [Related]
10. Impact of inter-individual differences in drug metabolism and pharmacokinetics on safety evaluation. Dorne JL Fundam Clin Pharmacol; 2004 Dec; 18(6):609-20. PubMed ID: 15548231 [TBL] [Abstract][Full Text] [Related]
12. Using physiologically-based pharmacokinetic modeling to address nonlinear kinetics and changes in rodent physiology and metabolism due to aging and adaptation in deriving reference values for propylene glycol methyl ether and propylene glycol methyl ether acetate. Kirman CR; Sweeney LM; Corley R; Gargas ML Risk Anal; 2005 Apr; 25(2):271-84. PubMed ID: 15876203 [TBL] [Abstract][Full Text] [Related]
13. In silico screening of chemicals for bacterial mutagenicity using electrotopological E-state indices and MDL QSAR software. Contrera JF; Matthews EJ; Kruhlak NL; Benz RD Regul Toxicol Pharmacol; 2005 Dec; 43(3):313-23. PubMed ID: 16242226 [TBL] [Abstract][Full Text] [Related]
14. Final report on the safety assessment of capsicum annuum extract, capsicum annuum fruit extract, capsicum annuum resin, capsicum annuum fruit powder, capsicum frutescens fruit, capsicum frutescens fruit extract, capsicum frutescens resin, and capsaicin. Int J Toxicol; 2007; 26 Suppl 1():3-106. PubMed ID: 17365137 [TBL] [Abstract][Full Text] [Related]
15. Chronic oral LOAEL prediction by using a commercially available computational QSAR tool. Rupp B; Appel KE; Gundert-Remy U Arch Toxicol; 2010 Sep; 84(9):681-8. PubMed ID: 20224925 [TBL] [Abstract][Full Text] [Related]
16. In silico classification of human maximum recommended daily dose based on modified random forest and substructure fingerprint. Cao DS; Hu QN; Xu QS; Yang YN; Zhao JC; Lu HM; Zhang LX; Liang YZ Anal Chim Acta; 2011 Apr; 692(1-2):50-6. PubMed ID: 21501711 [TBL] [Abstract][Full Text] [Related]
17. Evaluation of the uncertainty factor for subchronic-to-chronic extrapolation: statistical analysis of toxicity data. Pieters MN; Kramer HJ; Slob W Regul Toxicol Pharmacol; 1998 Apr; 27(2):108-11. PubMed ID: 9671565 [TBL] [Abstract][Full Text] [Related]
18. Modeling oral rat chronic toxicity. Mazzatorta P; Estevez MD; Coulet M; Schilter B J Chem Inf Model; 2008 Oct; 48(10):1949-54. PubMed ID: 18803370 [TBL] [Abstract][Full Text] [Related]
19. Deriving a data-based interspecies assessment factor using the NOAEL and the benchmark dose approach. Bokkers BG; Slob W Crit Rev Toxicol; 2007 Jun; 37(5):355-73. PubMed ID: 17612951 [TBL] [Abstract][Full Text] [Related]
20. Development of quantitative structure-activity relationship (QSAR) models to predict the carcinogenic potency of chemicals I. Alternative toxicity measures as an estimator of carcinogenic potency. Venkatapathy R; Wang CY; Bruce RM; Moudgal C Toxicol Appl Pharmacol; 2009 Jan; 234(2):209-21. PubMed ID: 18977375 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]